Acetoacetic Acid

Acetoacetic Acid

SCHEMBL491497

CC(=O)CC(=O)O.OCC(O)CO

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.41
KDM6B O15054 1/20 0.41
KDM5C P41229 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
LDHA P00338 1/20 0.38
SRR Q9GZT4 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
OR51E2 Q9H255 1/20 0.36
SLC15A2 Q16348 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
TGFBR1 P36897 1/20 0.33
MAPT P10636 1/20 0.33
GABRR1 P24046 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetoacetic Acid SCHEMBL29155554 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL648595 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL491475 1.00 LMNA (0.45) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL5795622 0.89 TGFBR1 (0.40) LMNAALDH1A1KDM4EKDM6BKDM5C
Glycerin SCHEMBL28122415 0.89 KDM4E (0.46) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL2005043 0.89 KDM4E (0.37) LMNAALDH1A1KDM4EKDM6BKDM5C
Glycerin SCHEMBL28686701 0.87 ALDH1A1 (0.53) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL27153879 0.87 THRB (0.54) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL28640192 0.85 TDP1 (0.50) LMNAALDH1A1KDM4EKDM6BKDM5C
Acetoacetic Acid SCHEMBL1058961 0.85 TDP1 (0.50) LMNAALDH1A1KDM4EKDM6BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113966323-B Method for producing ketocarboxylic acid polyol-based esters 凯托利皮克斯治疗有限责任公司 2023-11-28 CN claimed
CN-114008015-A Process for preparing polyol esters of hydroxycarboxylic acids, in particular polyglycerol esters IOI油脂化学品有限责任公司 2022-02-01 CN claimed
CN-113966323-A Method for producing ketocarboxylic acid polyol ester IOI油脂化学品有限责任公司 2022-01-21 CN claimed
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others TODAY, INC. (US) 2026-05-12 US disclosed
US-12286534-B2 Binder for an aqueous coating composition ALLNEX AUSTRIA GMBH (AT) 2025-04-29 US disclosed
US-20240425643-A1 FOAM COMPOSITIONS AMRIZE TECHNOLOGY SWITZERLAND LLC (CH) 2024-12-26 US disclosed
US-12098240-B2 Foam compositions HOLCIM TECHNOLOGY LTD (CH) 2024-09-24 US disclosed
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS TODAY, INC. (US) 2024-09-12 US disclosed
US-12071498-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2024-08-27 US disclosed
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others Today Inc. (US) 2024-07-02 US disclosed
CN-114008015-B Process for the preparation of polyhydric alcohol esters of hydroxycarboxylic acids, in particular polyglycerol esters 凯托利皮克斯治疗有限责任公司 2024-02-20 CN disclosed
US-20050004155-A1 Use of methylnaltrexone to treat irritable bowel syndrome PROGENICS PHARMACEUTICALS, INC. 2005-01-06 US disclosed
US-20040259899-A1 Combination therapy for constipation PROGENICS PHARMACEUTICALS, INC. 2004-12-23 US disclosed
WO-2004091622-A1 THE USE OF PERIPHERAL OPIOIS ANTAGONISTS, ESPECIALLY METHYLNALTREXONE TO TREAT IRRITABLE BOWEL SYNDROME PROGENICS PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed
WO-2004091665-A1 COMBINATION THERAPY FOR CONSTIPATION COMPRISING A LAXATIVE AND A PERIPHERAL OPIOID ANTAGONIST PROGENICS PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed
CN-1316902-A Therapeutic compositions (II) BTG INT LTD (GB) 2001-10-10 CN disclosed
US-4970143-A BICARBONATE BUFFER SOLUTION NESTEC S.A. (CH) 1990-11-13 US disclosed
EP-0037943-B1 PHARMACEUTICAL COMPOSITION FOR INTRARECTAL ADMINISTRATION, AND SUPPOSITORY PREPARED THEREFROM TEIJIN LIMITED (JP) 1985-08-14 EP disclosed
US-4434159-A PEPTIDE HORMONES, POLYSACCHARIDES, ABSORPTION AIDS TEIJIN LIMITED (JP) 1984-02-28 US disclosed
EP-0037943-A2 Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom TEIJIN LIMITED (JP) 1981-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others SLC2A9, GYS1, SLC2A8 LMNA 3333/4885ALDH1A1 350/4885KDM4E 1504/4885
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS CPT1B, GK, CPT1A LMNA 1973/4885ALDH1A1 1249/4885KDM4E 3282/4885
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others CPT1B, GK, CPT1A LMNA 1973/4885ALDH1A1 1249/4885KDM4E 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.